Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Table 1

Immune checkpoint inhibitors (monoclonal antibodies) that target PD-1, PD-L1, or CTLA-4 used in different types of cancer.

Immune checkpoint inhibitor	Target	Malignancy
Pembrolizumab (Keytruda) and nivolumab (Opdivo)	PD-1	Melanoma of the skin, non-small-cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, and Hodgkin’s lymphoma
Atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi)	PD-L1	Bladder cancer, non-small-cell lung cancer, and Merkel cell carcinoma
Ipilimumab (Yervoy)	CTLA-4	Skin melanoma